Regeneration Stack
PreclinicalBPC-157 + TB-500 + GHK-Cu Stack
This three-peptide combination brings together three of the most researched tissue repair compounds in the peptide space. BPC-157 promotes healing through multiple pathways including growth factor signaling and nitric oxide. TB-500 supports cell migration and tissue repair through actin regulation. GHK-Cu stimulates collagen production, wound healing, and gene expression modulation through copper peptide signaling. Each has its own evidence base, but the combination has not been studied as a unified protocol. Here is what the research shows for each component.
Science simplified
This stack combines three peptides that each support tissue repair through different biological pathways. BPC-157 promotes blood vessel growth and growth factor signaling. TB-500 helps cells move to injury sites. GHK-Cu triggers collagen production and modulates gene expression. The idea is that combining different repair mechanisms may produce broader healing support. No study has ever tested these three together.
Best researched for
Each component individually · tissue repair · wound healing
Evidence stage
Zero combination data · individual components L2–L3
Approval status
Not FDA-approved · investigational
0
Indexed Studies
Preclinical
Evidence Level
None
Human Trial Data
Research
Approval Status
PSI OVERVIEW
The BPC-157 + TB-500 + GHK-Cu combination represents the most comprehensive tissue repair stack discussed in peptide therapy communities. The rationale is pharmacologically sound — each compound acts through a different mechanism, potentially creating complementary repair signaling. BPC-157 activates VEGF and NO pathways. TB-500 upregulates actin for cell migration. GHK-Cu modulates gene expression across over 4,000 genes involved in tissue remodeling. PSI rates this combination L1 because no study has ever tested these three compounds together. The individual evidence ranges from L2 to L3. The logic is plausible, but the combination is entirely untested. Each component should be evaluated on its own evidence page.
Mechanism of Action
In everyday terms: Think of this stack as three different repair crews working simultaneously. BPC-157 brings blood supply and growth signals to the injury. TB-500 helps cells physically move to where they are needed. GHK-Cu tells your genes to produce more collagen and repair proteins. Each crew works independently, but together they may cover more repair ground. This has never been tested as a combination.
The three components target distinct biological pathways. BPC-157 promotes angiogenesis through VEGF upregulation and modulates the nitric oxide system, directing blood flow and growth factors to injured tissue. TB-500 regulates actin polymerization via the LKKTET motif, enabling cell migration and tissue flexibility at wound sites. GHK-Cu is a copper-binding tripeptide that modulates expression of over 4,000 genes involved in tissue remodeling, collagen synthesis, and anti-inflammatory signaling.
What is this stack being studied for?
No study has tested this combination. Evidence ratings below reflect the stack as a whole (L1). See individual compound pages for component-level evidence.
Tissue Repair & Wound Healing
PreclinicalBPC-157 (L3 individually) promotes wound healing through VEGF and NO pathways. TB-500 (L2) supports cell migration via actin regulation. GHK-Cu (L2) stimulates collagen synthesis and modulates wound healing genes. The combination is untested.
Musculoskeletal Recovery
PreclinicalEach component has independent animal data for muscle, tendon, or joint repair. The combination is commonly used in functional medicine for sports injuries and post-surgical recovery, but no controlled data exists for the stack.
Skin Rejuvenation
PreclinicalGHK-Cu has the strongest skin evidence (topical studies). BPC-157 and TB-500 may support deeper tissue repair. The combination for skin applications is anecdotal only.
Anti-inflammatory Effects
PreclinicalAll three compounds show anti-inflammatory effects through different mechanisms. Whether combining them produces additive, synergistic, or redundant effects is unknown.
PSI Verdict
Supported by evidence
Each component has an independent evidence base: BPC-157 (L3, 212 studies), TB-500 (L2, 1,050 studies), GHK-Cu (L2, 186 studies). The mechanisms are complementary — different receptor targets and signaling pathways. The rationale for combining tissue repair peptides with different mechanisms is pharmacologically reasonable.
Not yet established
Whether the three-compound combination produces effects superior to any individual component. Whether the components interact pharmacokinetically or pharmacodynamically when co-administered. The safety profile of the combination. Optimal ratios and timing. No published research exists on this specific 3-compound stack.
Stack Components
Molecular data for each component.
Research Evidence
No published research exists on this three-compound combination. The evidence below summarizes what is known about each component individually and why the combination is theoretically plausible but scientifically unvalidated.
BPC-157 has 212+ indexed studies showing consistent tissue repair across tendons, ligaments, gut, and liver in animal models
The strongest individual evidence base in this stack. L3 reflects limited but existing human data.
TB-500 has 1,050+ indexed studies documenting actin regulation, cell migration, and wound healing
Extensive basic science research. L2 reflects the absence of controlled human trials for systemic use.
GHK-Cu modulates expression of over 4,000 human genes involved in tissue remodeling
Unique gene expression modulation mechanism. L2 reflects strong mechanistic data with limited clinical translation.
The three mechanisms are largely non-overlapping: angiogenesis, cytoskeletal regulation, and gene expression
This non-overlap is the primary pharmacological rationale for combining them. It does not prove synergy.
Zero published studies test any two of these compounds together, let alone all three
This is the single most important fact about this stack. Community popularity does not substitute for research.
Safety Profile
No safety data exists for this three-compound combination. Each component has preclinical safety data independently. BPC-157 and TB-500 were placed on the FDA's Category 2 restricted list and are expected to return to Category 1 following the February 2026 HHS announcement. GHK-Cu injectable was also Category 2 and expected to return to Category 1. Combining multiple investigational compounds increases uncertainty about interactions and side effects.
Comparison: This Stack vs Individual Components
The key question is whether combining three compounds provides meaningful benefit over using one individually. No data answers this question. The comparison below highlights what is known about each component to help evaluate the trade-off between complexity and evidence.
Frequently Asked Questions
Questions to Ask Your Doctor
If you are considering discussing this combination with a healthcare provider, these questions can help start an informed conversation.
Explore Related Research
Side-by-side research comparisons with related compounds.
How to Choose
Decision guidance based on existing evidence — not a recommendation.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician DirectoryMedical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.